EI
RXII

EAM Investors’s GALENA BIOPHARMA INC COM RXII Stock Holding History

EAM Investors’s Portfolio RXII Stock Details RXII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-249,401
Closed -$1.24M – 410
2013
Q4 		$1.24M Buy
+249,401
New +$1.24M 0.22% 245

Other funds holding RXII

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

EAM Investors's RXII Position: Q1 2014 in Review

EAM Investors sold out of GALENA BIOPHARMA INC COM (RXII) in Q1 2014, closing a stake of 249,401 shares — an estimated $1.24M sold.

EAM Investors first reported a position in RXII in Q4 2013 and held it in 1 quarter. The position peaked at $1.24M in Q4 2013. 88 funds tracked by Wall St. Rank hold RXII as of Q1 2014.

  • EAM Investors reported no remaining GALENA BIOPHARMA INC COM position as of Q1 2014 after selling out during the quarter.
  • EAM Investors sold 249,401 GALENA BIOPHARMA INC COM shares in Q1 2014, an estimated $1.24M.
  • EAM Investors first reported a position in GALENA BIOPHARMA INC COM in Q4 2013 and held it in 1 quarter.
  • EAM Investors's GALENA BIOPHARMA INC COM position peaked at $1.24M in Q4 2013.
  • 88 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q1 2014.

Based on EAM Investors's 13F filing for Q1 2014, filed 15 May 2014.